File(s) not publicly available
Reason: No enhanced material.
Pylera® (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a guide to its use in Europe
online resourceposted on 09.04.2018 by Katherine Lyseng-Williamson
Any type of resource available online.
Compliance with ethical standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: K.A. Lyseng-Willilamson is a salaried employee(s) of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
Additonal information about this Adis Drug Review can be found here.
Pylera® comprises three (bismuth subcitrate potassium+ metronidazole + tetracycline hydrochloride) of four components of bismuth-based quadruple therapy for the eradication of Helicobacter pylori (H. pylori) in a single capsule. The 10-day regimen consists of the relatively convenient administration of Pylera® four times daily + twice-daily administration of the proton pump inhibitor omeprazole. This regimen provides an effective, well tolerated and relatively convenient option for administering bismuth-based quadruple therapy, which a recommended first- and second-line treatment for H. pylori eradication. The Pylera® regimen effectively eradicated H. pylori, regardless of the treatment-line, resistance of the bacterial strain to metronidazole and/or clarithromycin, the type of gastric disease and the country of treatment. The regimen is well tolerated, with a tolerability profile that is consistent with those of the individual components taken separately. Access to the full article can be found here.
© Springer International Publishing AG, part of Springer Nature 2017